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ABSTRACT 
The use of alternative promoters for the cell type-specific expression of a given 
mRNA/protein is a common cell strategy. NEMO is a scaffold protein required for 
canonical NF-κB signaling. Transcription of the NEMO gene is primarily controlled by 
two promoters: one (promoter B) drives NEMO transcription in most cell types and the 
second (promoter A) is largely responsible for NEMO transcription in liver cells. Herein, 
we have used a CRISPR/Cas9-based approach to disrupt a core sequence element of 
promoter B, and this genetic editing essentially eliminates expression of NEMO mRNA 
and protein in 293T human kidney cells. By cell subcloning, we have isolated targeted 
293T cell lines that express no detectable NEMO protein, have defined genomic 
alterations at promoter B, and do not support canonical NF-κB signaling in response to 
treatment with tumor necrosis factor (TNF). Nevertheless, non-canonical NF-κB 
signaling is intact in these NEMO-deficient cells. Expression of ectopic NEMO in the 
edited cells restores downstream NF-κB signaling in response to TNF. Targeting of the 
promoter B element does not substantially reduce NEMO expression (from promoter A) 
in the human SNU-423 liver cancer cell line. We have also used homology directed 
repair (HDR) to fix the promoter B element in a 293T cell clone. Overall, we have 
created a strategy for selectively eliminating cell type-specific expression from an 
alternative promoter and have generated 293T cell lines with a functional knockout of 
NEMO. The implications of these findings for further studies and for therapeutic 
approaches to target canonical NF-κB signaling are discussed. 
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INTRODUCTION 
 
Much of the gene diversity in humans is generated by the use of alternative 
splicing and alternative promoters (Ayoubi & Van De Ven, 1996: Davulri et al., 2008). It 
is estimated that over 50% of human genes have alternative splicing and/or use 
alternative promoters, and alternative promoter usage has also been coupled to alternative 
splicing (Modrek & Lee, 2002; Davuluri et al., 2008; Xin et al. 2008). In many cases, 
alternative promoters are used for the tissue-specific or developmentally timed expression 
of a given gene, and abnormal alternative splicing or promoter usage has been associated 
with human disease, especially cancer (Davuluri et al. 2008; David & Manley, 2010; 
Zhang & Manley, 2013; Vacik & Rasda, 2017). For some genes, alternative promoters 
direct the expression of an identical protein coding region in different cell types or under 
different conditions by virtue of the promoters being located upstream of distinct 5’ non-
translated exons that splice to a common set of downstream coding exons. Methods for 
assessing the function of tissue-specific alternative promoter usage for individual genes 
are limited. In this paper, we have used a CRISPR/Cas9-based targeting approach to 
investigate cell type-specific promoter expression of a key gene (NEMO) in NF-κB 
signaling. 
The mammalian NF-κB transcription factor is involved in the regulation of many 
cell and organismal processes (Hayden & Ghosh, 2012). NF-κB itself is tightly regulated 
by subcellular localization: that is, NF-κB is located in the cytoplasm when inactive, and 
is induced to translocate to the nucleus when activated by upstream signals. In canonical 
NF-κB signaling, NF-κB is activated by IKKβ-mediated phosphorylation of the NF-κB 
inhibitor IκB, which is then degraded to allow NF-κB to enter the nucleus. In non-
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canonical signaling, cytoplasmic NF-κB p100 is phosphorylated by IKKα, an event that 
induces proteasome-mediated processing of p100 to p52, which then enters the nucleus to 
affect gene expression (Sun, 2011).     
 NEMO (NF-κB Essential MOdulator) is a protein that serves as a scaffold for 
IKKβ in canonical NF-κB signaling (Maubach et al., 2017). In the absence of NEMO, 
canonical NF-κB signaling cannot be activated (Schmidt-Supprian et al., 2000). In 
contrast, activation of non-canonical processing of NF-κB p100 generally does not 
require NEMO (Sun, 2011). As such, NEMO is a key regulator for activation of the 
canonical NF-κB pathway by a variety of upstream signals, and NEMO serves to 
distinguish activation of canonical and non-canonical NF-κB pathways.    
 NEMO is also involved in human disease in two prominent ways. First, mutations 
in the NEMO gene (IKBKG, chromosome X), which often compromise the ability of 
NEMO to support activation of NF-κB, lead to a variety of developmental and 
immunodeficiency diseases in humans (Courtois & Gilmore, 2006; Maubach et al., 
2017). Second, NEMO is required for the constitutive and chronic activation of canonical 
NF-κB signaling that occurs in a variety of cancers and is required for the ability of these 
cancer cells to proliferate or survive (i.e., avoid apoptosis) (Maier et al., 2013; Maubach 
et al., 2017; Puar et al., 2018). Therefore, inhibition of canonical NF-κB signaling can 
inhibit proliferation or induce apoptosis in a variety of cell- and animal-based cancer 
models (Puar et al., 2018). However, enthusiasm for NF-κB-directed inhibition for cancer 
therapy was greatly dampened by the finding that systemic and genetic inhibition of 
canonical NF-κB in animal models leads to liver toxicity and often cancer (Grivennikov 
et al., 2010; Luedde & Schwabe, 2011). For example, mice with liver-specific knockouts 
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of NEMO develop liver damage and sometimes cancer (Luedde et al., 2007; Beraza et al., 
2009).  
We had three goals in this research: 1) to demonstrate that CRISPR-based 
targeting of an alternative promoter can be used to knock down expression of a gene in a 
cell type-specific manner; 2) to create a NEMO-deficient, highly transfectable human cell 
line for NEMO mutant analysis; and 3) to establish a proof-of-principle concept for 
targeting the NF-κB signaling pathway for disease therapy in a way that might 
circumvent unwanted side effects in the liver.  
 
RESULTS 
CRISPR-based targeting of a core promoter sequence in Exon 1B of the 
NEMO gene abolishes NEMO protein expression in HEK 293T cells. The human 
IKBKG gene (NEMO, herein), encoding the NEMO protein, has four alternative 5’ non-
coding exons (1D, 1A, 1B, 1C) that direct transcription in a tissue-specific fashion (Fusco 
et al., 2006) (Fig. 1A). Exon 1B is the most commonly used first exon in most cell types, 
and this region has a strong RNApolII, H3K4-me3 and DNAse hypersensitivity peaks in 
human HEK 293 cells (Fusco et al., 2006) (Fig. 1A). Moreover, the exon 1B-containing 
mRNA is part of the major NEMO transcript found on polysomes in human 293T 
embryonic kidney cells (Floor & Doudna, 2016). Within exon 1B, we noted a sequence 
(ACCGCGAAACT) that is just downstream of a major transcription start site (TSS) of 
the NEMO gene and that is within a consensus sequence which is located near the TSS of 
many genes (Vo Ngoc et al., 2017a) (Fig. 1A). Based on these cumulative observations, 
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we put forth the hypothesis that this sequence is important for efficient transcription of 
the NEMO gene in 293T cells.  
As a first step in testing that hypothesis, we sought to disrupt the predicted exon 
1B core promoter element by CRISPR/Cas9 targeting in 293T cells using lentiviral 
transduction of Cas9 and a gRNA targeting the identified site. After puromycin selection, 
we performed anti-NEMO Western blotting on extracts from a pool of transduced 293T 
cells. As shown in Fig. 2A, the levels of NEMO protein were reduced in two independent 
pools of cells transduced with the lentivirus containing the targeting gRNA as compared 
to cells transduced with the same vector containing no gRNA. Equal levels of total 
protein (as judged by β-tubulin Western blotting) were present in both cell lysates, and 
the FLAG-tagged Cas9 protein was expressed in all transduced cells (Fig. 2A). 
In an effort to identify a clone of cells with a total disruption of the targeted exon 
1B promoter sequence, we picked several clones of puromycin-selected cells transduced 
with the NEMO-targeting lentivirus. Screening of those cell clones by anti-NEMO 
Western blotting enabled us to identify a cell clone (clone 1) that expressed less than 5% 
of the NEMO protein expressed in the parental, wild-type 293T cells (Fig. 2B). A second 
targeted cell clone (clone 2) had clearly reduced levels of NEMO protein, whereas a 
clone of 293T cells targeted with a gRNA located downstream of exon 1B (clone C, Fig. 
2B) did not have reduced NEMO protein expression as compared to parental 293T cells.   
To characterize the genomic disruptions in clone 1, we used PCR to amplify the 
region surrounding the gRNA-targeted site and subjected the pooled PCR product to next 
generation sequencing. We obtained approximately 34,000 sequence reads from the 
targeted region in clone 1 cells. All relevant sequences from clone 1 cells had disruptions 
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within the predicted gRNA site, and all had disruptions within the consensus core 
promoter sequence (ACCGCGAAACT). With a cutoff of 0.26% of total reads, we 
identified 42 genomic disruptions at the targeted site in clone 1 cells (Fig. S1). The major 
genomic disruption (comprising 27.7% of the reads) had a one base pair deletion in the 
non-variant AAA sequence in the consensus sequence (i.e., from ACCGCGAAACT to 
ACCGCG_AACT) (Fig. 2C). These results make three points: 1) based on the depth of 
sequencing, there are few, if any, wild-type exon 1B sequences within clone 1; 2) there is 
genomic heterogeneity at the targeted site within clone 1; and 3) the lack of NEMO 
protein in clone 1 is likely due to disruption of the targeted sequence, even by as little as 
a 1-bp deletion. 
 We next compared the expression of NEMO mRNA in wild-type 293T cells and 
clone 1 cells. First, we used qPCR to compare the total NEMO mRNA in the wild-type 
and clone 1 cells, by using primer sets downstream of the targeted upstream region, i.e., 
in exons 2 and 3 or in exons 6 and 7. As shown in Fig. 2D, the total NEMO mRNA was 
reduced by at least 50-fold in clone 1 cells. Similarly, using primers in exon 1B and in the 
proximal first intron to detect unspliced NEMO pre-mRNA, we detected an appropriately 
sized band in RNA from wild-type 293T cells, but no amplified product when using RNA 
from clone 1 cells (Fig. 2E). The levels of control GAPDH mRNA were similar in both 
cell types (Fig. 2E). Thus, the levels of pre- and mature NEMO mRNA are greatly 
reduced in clone 1 cells, which have a variety of genomic deletions in a consensus exon 
1B core promoter sequence, and these disruptions likely account for the lack of NEMO 
mRNA and consequently NEMO protein expression in clone 1 cells. 
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Clone 1 cells are defective for induced activation of NF-κB signaling. To 
determine whether the lack of NEMO expression renders clone 1 cells defective for NF-
κB signaling, we compared the activation of NF-κB signaling in wild-type and clone 1 
cells in response to a variety of agents (TNFα, and DNA-damaging agents camptothecin, 
VP16, doxorubicin, and gamma irradiation). As shown in Fig. 3A, clone 1 cells did not 
show increased nuclear NF-κB DNA-binding activity in response to any of these agents, 
whereas control 293T cells showed robust induction of nuclear NF-κB DNA-binding 
activity. Moreover, induced phosphorylation of IκBα was not detected in clone 1 cells in 
response to any of these agents (Fig. 3A), but was seen in control 293T cells. As controls, 
we show that β-tubulin expression and Oct DNA-binding activity are similar in wild-type 
and clone 1 cells, under all conditions (Fig. 3A). 
To confirm that the lack of responsiveness of clone 1 cells to NF-κB-activating 
agents was due to the loss of NEMO expression, we transfected clone 1 cells with an 
expression vector for FLAG-NEMO (which lacks the 5’ exon 1B sequences and is 
therefore not susceptible to gRNA targeting), and then treated the cells with TNFα. As 
shown in Fig. 3B, re-expression of NEMO in clone 1 cells restored TNFα-induced 
phosphorylation of IκBα as well as nuclear translocation of NF-κB subunit p65. Taken 
together, these results indicate that clone 1 cells are specifically defective for stimulus-
based activation of canonical NF-κB signaling, and that TNFα-induced activation of NF-
κB signaling in clone 1 cells can be restored by re-expression of NEMO. 
 
Reduced genomic heterogeneity in a subclone of clone 1 cells. Because of the 
heterogeneity of CRISPR/Cas9-directed genomic deletions at the NEMO core promoter 
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site in clone 1 cells, we sought to isolate a cell clone with a reduced number of genomic 
disruptions at the targeted site. Therefore, we made cell subclones by plating clone 1 cells 
at less than one cell per well. Five such cell subclones were then expanded and analyzed. 
Like parental clone 1 cells, all subclones expressed no detectable NEMO protein (Fig. 
4A). Preliminary sequence analysis indicated that clone 1.1 had the least genomic 
complexity around the targeted site, and so clone 1.1 was the focus of further analysis. As 
shown in Fig. 4B, analysis of ~16,000 sequence reads of a PCR product covering the 
genomic disruption of clone 1.1 cells showed that over 99% of the reads contained an 8-
bp deletion at the targeted site (and about 0.9% of the reads had a 1-bp deletion of an A 
residue in the triplet of the consensus sequence, i.e., ACCGCG-AACT). A second cell 
subclone (clone 1.3) had over 80% of its total reads (9,485) showing a 2-bp deletion in 
the AAA stretch of the consensus sequence (ACCGCG--ACT). As a second method of 
confirming the genomic editing at the target site in clone 1.1 cells, we used PCR 
amplification of the targeted site followed by restriction digestion with BsiEI, as there is 
a BsiEI restriction enzyme site at the wild-type target sequence (see Fig. S2) that would 
be destroyed by the 8-bp deletion in clone 1.1 genomic DNA. As predicted, the PCR 
product amplified from control 293T cell genomic DNA was digested by BsiEI, but the 
PCR product from clone 1.1 cell genomic DNA was not digested by BsiEI (Fig. 4C). 
 To characterize further the 1.1 and 1.3 cell subclones, we first assessed whether 
IκBα was phosphorylated in these cells in response to TNFα. As shown in Fig. 4D, 1.1 
and 1.3 cells transfected with an empty vector did not show phosphorylation of IκBα 
following treatment with TNFα, whereas clone 1.1 and 1.3 cells transfected with a 
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NEMO expression vector showed readily detectable TNFα-induced phosphorylation of 
IκBα.  
       Activation of non-canonical NF-κB signaling, which occurs by IKKα-directed 
phosphorylation and processing of NF-κB p100, has generally been found to be 
independent of NEMO (Sun, 2011). Consistent with these findings, overexpression of 
NIK, an activator of non-canonical NF-κB signaling, led to equal levels of NF-κB p100 
processing to p52 in both wild-type 293T and clone 1.1 cells (Fig. 4E). Of note, the 
FLAG-Cas9 protein is still expressed in clone 1.1 cells, even after subcloning and 
extensive passaging (Fig. 4F). 
 
HDR-mediated repair of the 8-bp deletion in 1.1 cells.  To demonstrate that 
NEMO lesions can be repaired, we attempted HDR-mediated repair of the 8-bp deletion 
locus in clone 1.1 cells. To do so, we co-transfected 1.1 cells with an expression vectors 
for a gRNA-directed against the site that was created by the 8-bp deletion and for a 
single-stranded repair oligo that also had a mutation (GGG->GAG) which abolished the 
adjacent PAM site used for the gRNA (see Table S2). The PAM site mutation was 
included so that the original gRNA and Cas9 in these cells could not target the repaired 
allele and so that we could confirm that the repair had occurred (and was not, for 
example, due to contamination). PCR amplification and BsiEI digestion of the targeted 
locus from HDR-transfected 1.1 cells showed that approximately 5-10% of the PCR-
amplified product was digested with BsiEI (that is, a titration of wild-type DNA, 
indicated that approximately 5-10% of the PCR product from HDR-transfected 1.1 cells 
was digested with BsiEI [not shown]). Moreover, next generation sequencing showed 
 
 
11 
that 11.5% of ~40,000 sequence reads had the wild-type sequence in place of the 8-bp 
deletion and also had the introduced GAG mutation in the adjacent PAM site (Fig. S3).  
        
Expression of G6PD from the bi-directional promoter is not affected in clone 
1.1 cells. The NEMO exon 1B promoter is a bi-directional GC-rich (TATA box-lacking) 
promoter (Galgóczy et al., 2001; Fusco et al., 2012). That is, on the opposite DNA strand 
in the opposite direction, there are multiple transcriptional start sites for the G6PD gene. 
Western blotting showed that expression of glucose-6-phosphate 1-dehydrogenase 
protein is not altered in clone 1.1 cells as compared to control cells (Fig. 4G). Therefore, 
the 8-bp deletion in clone 1.1 cells is unlikely to have an effect on G6PD transcription, 
indicating that the 8-bp deletion inactivates the bi-directional promoter only for NEMO 
expression. 
 
Treatment of 293T cells with the gRNA against the exon 1B core promoter 
element and dCas9 also reduces NEMO expression. Based on the above experiments, 
we reasoned that other methods of targeting the exon 1B region might result in reduced 
NEMO expression. In particular, targeting of genomic regions with dCas9, which has 
mutations in its catalytic residues required for DNA-cleaving activity, has been shown to 
block specific gene expression under some conditions (Lawhorn et al., 2014; Fulco et al., 
2016). Therefore, we first created a version of pLenti-CRISPR2.0 in which Cas9 was 
mutated at residues 10 and 840 (D10G and H840A), which inactivates the DNA cleaving 
function of Cas9 (Qi et al., 2013). As above, we then selected 293T cells that had been 
transduced with the pLenti-CRISPR2.0-dCas9 vector containing the NEMO exon 1B 
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gRNA. We then measured NEMO expression by Western blotting in pools and clones of 
puromycin-selected cells. As shown in Fig. 5A, NEMO expression was reduced in two of 
three pLenti-CRISPR2.0-dCas9 cell clones containing the exon 1B gRNA and in a pool 
of transduced cells, as compared to the uninfected control 293T cells. As a control, no 
NEMO protein was detected in a lysate from clone 1.1 cells (Fig. 5A). The extent of 
NEMO protein knockdown in the pool of CRISPR2.0-dCas9 cells containing the NEMO 
exon 1B gRNA was similar to that seen in cells with the exon 1B gRNA and wild-type 
Cas9 (compare Fig. 5A to Fig. 2A). As a further control, we show that the dCas9 protein 
was expressed in cell clones d2 and d3. Moreover, no dCas9 protein was expressed in 
clone d1, likely explaining why there was no reduction in NEMO protein in those cells 
(Fig. 5A). In addition, G6PD protein expression was not affected in clones or pools of 
cells with reduced NEMO protein from dCas9/gRNA transduction (Fig. 5B). Finally, we 
sequenced the gRNA target site in the genomic DNA from clones d2 and d3. As 
expected, none of the amplified products for clones d2 and d3 (0 out of 47,208, and 
23,507, respectively; data not shown) had genomic alterations at the target site, indicating 
that the dCas9 protein expressed in these clones is defective for genome editing. Taken 
together, the results in this section indicate that occupation of the NEMO exon 1B core 
promoter target site by the gRNA-dCas9 complex blocks efficient transcription of NEMO 
in 293T cells.  
 
CRISPR/Cas9 targeting of the NEMO exon 1B core promoter element does 
not abolish NEMO expression in a human liver cell line. Fusco et al. (2006) reported 
that the exon 1D promoter is the major promoter used for NEMO transcription in liver 
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cells, with approximately 14-fold higher expression of mRNA from exon 1D than exon 
1B in both adult human liver tissue and the HepG2 liver cell line. Therefore, we 
hypothesized that CRISPR-Cas9-based targeting of the exon 1B core promoter sequence 
would not substantially affect NEMO expression in liver cells. To test this hypothesis, we 
transduced SNU-423 human liver cells with our pLenti-Crispr2.0 gRNA-containing 
vector and selected cells with puromycin. As shown in Fig. 6A, a puromycin-resistant 
clone of SNU-423 cells (clone L1) transduced with the gRNA vector expressed levels of 
NEMO protein that were essentially the same as the parental SNU-423 cells. As a 
control, we show that the clone LI cells expressed Cas9 (Fig. 6A). In addition, BseE1 
digestion of the targeted site in the L1 clone (Fig. 6B) and DNA sequencing of the 
targeted locus in exon 1B showed that approximately 96% of the ~41,000 sequence reads 
were disrupted by genome editing (Fig. 6C). qPCR showed that clone L1 cells expressed 
approximately 60-80% of the levels NEMO mRNA as parental SNU-423 cells (Fig. 6D). 
Western blots of four additional Lenti-Crispr2.0 gRNA-containing SNU-423 cell clones 
showed that they expressed similar amounts of NEMO as compared to control cells (Fig. 
S4). Overall, these results indicate that targeting of the NEMO exon 1B promoter does 
not substantially affect usage of the upstream liver-specific NEMO promoter 1D, and 
thus, does not dramatically reduce NEMO protein expression in a human liver cell line.   
 
DISCUSSION 
In this paper, we have shown that CRISPR-based targeting of a core promoter 
region of the most commonly used promoter of the NEMO gene can efficiently 
knockdown NEMO protein expression and function in human HEK 293T cells. 
 
 
14 
Moreover, targeting of this core promoter sequence only marginally affects NEMO 
expression in a human liver cell line, in which NEMO transcription is controlled by a 
distinct liver-specific promoter. Although other researchers have targeted gene regulatory 
regions by CRISPR-based screening (e.g., Sanjana et al., 2016), to our knowledge, this is 
the first use of CRISPR-based genetic editing to ablate expression of an individual gene 
in a cell type-specific manner.  
 Transcription of the NEMO gene in the majority of cell types is controlled by a 
GC-rich, bi-directional promoter (promoter B) that has multiple transcriptional start sites 
(Fusco et al., 2012), as is commonly found with GC-rich promoters (Vo Ngoc et al. 
2017b). The gRNA that we used to knockdown NEMO expression in 293T cells targets 
exon 1B core promoter sequences that are just downstream of a major NEMO TSS. Of 
note, this gRNA covers a sequence (ACCGCGAAACT) that is similar to one of four 
consensus sequences found near, and often downstream of, many eukaryotic/human TSSs 
(Vo Ngoc et al. 2017a) (Fig. 1A). This sequence is likely to be important for the initiation 
of transcription due to binding of a basal transcription protein or complex (Vo Ngoc et 
al., 2017a, 2017b). Consistent with the core sequence in the exon 1B promoter being a 
binding site for a transcription complex, we also found that targeting of dCas9 to this 
element blocks NEMO protein expression (Fig. 5). Although the consensus sequence 
logo for this 11-bp common promoter element is quite variable (Fig. 1A), it has three 
invariable A residues. Of note, all 42 of the genomic deletions in our initial 293T cell 
clone 1 have disruptions in this AAA sequence, including ~28% of the sequence reads 
that lack only a single A residue. Given that NEMO mRNA levels were reduced by at 
least 50-fold in clone 1 cells (Fig. 2D) and NEMO protein was essentially undetectable 
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(Fig. 3A), it is unlikely that there is any substantial NEMO mRNA expression from the 
~28% of NEMO alleles that have the 1-bp deletion in the clone 1 population. Moreover, 
approximately 90% of the edited alleles in clone 1.3 cells had 1 or 2 bp deletions in the 
AAA sequence (Fig. 4B) and expressed no detectable NEMO protein (Fig. 4A).  
The clone 1 cells were established from a cell clone that was generated on the first 
transduction step, and yet clone 1 cells had a highly diverse set of at least 42 disruptions 
at the targeted site (Fig. S1). We believe that the target site heterogeneity within this 
“clone” (clone 1) arose from at least two sources: 1) that not all NEMO alleles were 
targeted in the originally transduced cell and therefore, additional disruptions occurred 
after the first cell division; and 2) that some early arising targeted alleles underwent 
further editing after the first targeting event (e.g., a 1-bp deletion could have been further 
edited to an 8-bp deletion), since these cells stably express the NEMO gRNA and Cas9. 
In contrast, the subclone 1.1 cells were isolated some time after passage of the original 
clone 1 cells, and thus the NEMO alleles (and the 8-bp deletion) in 1.1 cells were likely 
stabilized in these clonally re-derived cells. In any event, the clone 1.1 cells (derived 
from the clone 1 cells) represent a nearly homogenous edited cell line that will likely be 
useful for researchers who seek to investigate NEMO protein function. 
 One common method to analyze NEMO mutant function is to re-express the 
NEMO protein in mouse NEMO knockout cells (Schröfelbauer et al., 2012; Cote et al., 
2013). Such experiments have two limitations: 1) human NEMO proteins are being 
analyzed in mouse cells, and 2) to establish pure, selected populations of NEMO 
reconstituted cells can take a month or more. The 1.1 cell line, which has a nearly 
homogenous and defined 8-bp deletion in exon 1B (Fig. 4B), is likely to be useful for the 
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rapid analysis of NEMO mutants, as occur in human disease or created in the lab. That is, 
in an experiment that took less than a week, we showed that transient transfection of 1.1 
cells with FLAG-NEMO can restore TNFα-induced phosphorylation of IκBα (Fig. 4D). 
Many cancers rely on canonical NF-κB signaling for growth and survival (Paur et 
al, 2018). Relevant to our study, a CRISPR-based screen found NEMO to be among the 
top 7% of targets for restricting the growth of B-lymphoma cells (Reddy et al., 2017), and 
lymphoid cells use promoter B for expression of NEMO (Fusco et al., 2006). Almost all 
approaches that have sought to target NF-κB function have been directed at NF-κB 
pathway protein targets (Gilmore & Garbati, 2011). The limitations of such protein-based 
approaches is that, without an efficient organ-specific delivery system, one will affect the 
NF-κB in non-cancer cells. In particular, such NF-κB-direct approaches have often 
resulted in liver toxicity because targeting of NF-κB signaling, and even disruption of 
NEMO itself, causes liver toxicity (Luedde et al., 2007; Grivennikov et al., 2010; Luedde 
& Schwabe, 2011). Our finding that gRNA-directed targeting of NEMO promoter B does 
not substantially affect liver-specific (promoter A) expression of NEMO (Figs. 6 and S4) 
suggests that targeting of the core promoter B sequence for the treatment of cancers that 
rely on canonical NF-κB signaling would not affect liver function in vivo. Precisely how 
one would target NEMO promoter B in vivo with CRISPR/Cas9 is not obvious; however, 
several gRNA/Cas9 in vivo delivery systems have been investigated (Dunbar et al., 2018; 
Glass et al., 2018). 
Finally, we have also shown that we can repair a NEMO mutation by HDR. That 
is, by HDR we provide evidence that we were able to correct the 8-bp promoter deletion 
in clone 1.1 cells (Fig. S3). This result establishes a precedent for repairing the small 
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genomic alterations in NEMO that have been found in human patients (Maubach et al., 
2017). 
Overall, we believe the methods, results, and cell lines generated in this paper will 
be of interest to others studying NEMO function, and can provide novel methods of gene 
targeting (possibly for therapeutic purposes) and for investigating in vivo effects of 
alternative promoter usage.  
  
MATERIALS AND METHODS  
Cell culture and plasmids. Human embryonic kidney 293T (HEK 293T) and 
SNU-423 cells (a gift of Ulla Hansen, Boston University) were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM; Thermo Fisher) with 10% Fetal Bovine Serum (FBS; 
Biologos), supplemented with 50 U/ml penicillin, and 50 µg/ml streptomycin) at 37 °C, 
5% CO2, in a humidified incubator.  
Detailed descriptions of all plasmids and primers used in this paper are presented 
in Tables S1 and S2. Plasmids pcDNA-FLAG, pcDNA-FLAG-NEMO have been 
described previously (Herscovitch et al., 2008). pLentiCRISPRv2.0 is from Addgene 
(plasmid # 52961; Sanjana et al., 2014). The gRNA sequences targeting the NEMO exon 
1B core promoter (quality score = 96; 39 off-target sites; crispr.mit.edu) or a control 
sequence (labelled C in Fig. 2B) slightly downstream of the exon 1B site (Table S2) were 
synthesized with overhangs and were ligated into BsmBI-digested plentiCRISPRv2.0. 
pLentiCRISPRv2.0-dCas9 plasmid was constructed using PCR site-directed overlap 
mutagenesis in two steps: first, both D10G, and H840A mutations were introduced via 
amplification with overlapping primers spanning the N, and C-terminal halves of dCas9 , 
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the resulting two fragments containing the N- and C-terminal halves of dCas9 were 
subcloned stepwise into a pSL1180 carrier plasmid. Finally, full-length dCas9 was then 
subcloned into the LentiCRISPR v2.0 plasmid, and confirmed by DNA sequencing. The 
relevant portions of plentiCRISPRv2.0-gRNA and pLentiCRISPRv2-dCas9 plasmids 
containing inserts were also verified by DNA sequencing. 
 
Establishment of CRISPR NEMO targeted cell lines. 293T cells were seeded at 
~60% confluence in a 100-mm tissue culture plates approximately 24 h prior to 
transfection. The next day, cells were co-transfected with 1 µg plentiCRISPR v2, 2 µg 
pCMV-dR8.91, and 4 µg pCMV-VSV-G along with 32 µg polyethylenimine (PEI) in a 1 
ml serum-free DMEM, and incubated for 15 min at room temperature. The PEI:DNA-
containing transfection mixture was diluted to 10 ml with DMEM/10% FBS, added to 
plates of 293T cells, and incubated overnight for approximately 16 h. On the next day, 
plates were washed once with PBS, and fluid changed with fresh DMEM/10% FBS. Cells 
were then incubated for two more days, and at that time, transfected cells were 
subcultured into new 100-mm plates with 10 ml DMEM/10% FBS. The following day, 
puromycin was added to a final concentration of 2.5 µg/ml. Plates were maintained under 
puromycin selection, and fluid changed approximately every 3-5 days, until distinct 
colonies had formed (at approximately 15 days after start of puromycin selection). Cell 
lines were established from single puromycin-resistant, and were screened for NEMO 
expression by Western Blotting (e.g., clone 1). After approximately eight passages, 
subclones of clone 1 cells were isolated by limiting dilution. That is, clone 1 cells were 
plated in a 96-well tissue culture plate at a density of 0.25 cells/well, and clones (e.g., 1.1 
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– 1.5) growing out of individual wells were re-screened for NEMO expression by 
Western blotting. 
 
Western blotting. Whole-cell extracts were prepared in AT lysis buffer (20 mM 
HEPES pH7.9, 150 mM NaCl, 1mM EDTA, 1 mM EGTA, 20% w/v glycerol, 1% v/v 
Triton X-100, and Roche Complete Protease Inhibitor). Extracts were then separated on a 
10% SDS-polyacrylamide gel, transferred to a nitrocellulose membrane in transfer buffer 
(20 mM Tris, 150 mM glycine, 20% methanol) overnight at 4 °C. To detect high 
molecular weight Cas9 and dCas9 proteins, whole-cell extracts were resolved on a 7.5% 
SDS-polyacrylamide gel, and transferred to nitrocellulose in low-methanol transfer buffer 
(20 mM Tris, 150 mM glycine, 20% methanol) at 250 mA for 1 h, followed by 170 mA 
overnight under 4 °C. Membranes were blocked in TMT (10 mM Tris-HCl pH 7.4, 150 
mM NaCl, 0.1% v/v Tween 20, 5% w/v Carnation nonfat dry milk) for 1 h at room 
temperature, incubated in the appropriate primary antibody overnight at 4 °C as follows: 
anti-NEMO (1:1000; #2689, Cell Signaling Technology), anti-phospho-IκBα (1:1000; 
#9246, Cell Signaling Technology), anti-FLAG (1:1000; #2368, Cell Signaling 
Technology), anti-HA (1:500; Y-11, Santa Cruz Biotechnology), anti-NF-κB p100 
(1:500; #4882, Cell Signaling Technology), anti-p65 (1:2000, #1226 gift of Nancy Rice), 
anti-tubulin (1:500), anti-G6PD (1:500, #12263, Cell Signaling Technology), and anti-
Cas9-HRP (1:10,000; ab202580, Abcam). Membranes were washed four times with 
TBST (10 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.1% v/v Tween 20). Membranes were 
then incubated with the appropriate secondary HRP-linked antibody as follows: anti-
rabbit-HRP (1:3000, Cell Signaling Technology) for NEMO, FLAG, Tubulin, p65, and 
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G6PD or anti-mouse-HRP (1:3000, Cell Signaling Technology) for anti-phospho-IκBα. 
Membranes were then washed three times with TBST, twice with TBS (10 mM Tris-HCl 
pH 7.4, 150 mM NaCl), and incubated for 5 min at room temperature with 
chemiluminesent HRP substrate (SuperSignal West Dura Extended Duration Substrate, 
Thermo Fisher). Immunoreactive bands were detected by exposing membranes to 
autoradiography film (GeneMate Blue Basic Autoradiography Film, BioExpress). 
 
Genomic DNA amplification and analysis. Genomic DNA was isolated from 
cultured cells by first lysing the cells in a buffer consisting of 10 mM Tris-HCl, pH 8, 
100 mM NaCl, 25 mM EDTA, 0.5% SDS, 1 mg/ml proteinase K. Samples were then 
heated for 2 h at 60°C, extracted with phenol two times and with chloroform once. DNA 
was precipitated with 100% ethanol for 30 min. Approximately 0.5 µg of genomic DNA 
was used in PCRs. For DNA sequence analysis of the targeted site, DNA was amplified 
by standard PCR using primers NEMO gExon 1B Fwd and NEMO gIntron 1 Rev (see 
Table S2). The PCR product was purified and then sent out for Next-Generation 
sequencing (MGH CCIB DNA Core). For restriction enzyme analysis of the edited site, 
DNA was amplified by standard PCR using primers gDNA Fwd and gDNA Rev (Table 
S2). From a 50 µl reaction, 7 µl was then digested with BsiEI (New England Biolabs) and 
analyzed by agarose gel electrophoresis followed by staining with ethidium bromide. 
 
HDR-mediated repair of the mutated NEMO allele in clone 1.1 cells. Clone 
1.1 cells were seeded at ~60% confluence in 35-mm tissue culture plates approximately 
24 h prior to transfection. The next day, cells were co-transfected with 1.8 µg of 
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px330puro-HDR (see Table S1), 0.2 µg of an 84-bp single-stranded HDR template 
(HDR-1.1; Table S2), along with Effectine reagents (QIAGEN; see below) in DMEM 
containing 10% FBS. On the next day, the transfection media was replaced with fresh 
DMEM/10% FBS. Two days later, cells were passaged into 60-mm plates with 5 ml 
DMEM/10%FBS. After allowing the cells to grow out, genomic DNA was isolated and 
target DNA was amplified by standard PCR using primers NEMO gExon 1B Fwd and 
NEMO gIntron 1 Rev (see Table S2). The PCR product was purified and subjected to 
Next-Generation sequencing (MGH CCIB DNA Core). 
 
RNA analysis by RT-PCR and qPCR. mRNA was isolated from cultured cells 
using TRIzol RNA purification kit (QIAGEN) according to the manufacturer’s 
instructions. cDNA was synthesized using random primers and M-MLV reverse 
transcriptase or the TaqMan cDNA synthesis kit (Thermo Fisher). For RT-PCR, NEMO 
cDNA was amplified by PCR for 32 cycles (using primers NEMO Exon 1B Fwd NEMO 
Intron 1 Rev [Table S2]), and DNA was then analyzed by polyacrylamide gel 
electrophoresis and staining with ethidium bromide. For qPCR, NEMO cDNA was 
amplified (using primers NEMO Exon 2 Fwd and NEMO Exon 3 Rev or NEMO Exon 6 
Fwd and NEMO Exon 7 Rev) using SYBR Green Real-Time PCR kit (Thermo Fisher), 
and analyzed on an ABI 7900ht qPCR machine. The delta delta CT method was used to 
quantify the relative fold change in gene expression, and values were normalized to 
NEMO mRNA expression in control 293T or SNU-423 cells. For RT-PCR and qPCR 
GAPDH mRNA was used as a control (see primers in Table S2).   
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    Cell treatments. 293T and clone 1 cells were treated with various NF-κB 
inducers (10 ng/ml TNFα for 30 min; 10 µM camptothecin for 2 h; 10 µM VP16 for 2 h; 
25 µM doxorubicin for 2 h; 5 Gy of ionizing irradiation and terminated after 1.5 h. A JL 
Sheperd model JL-10 with a cesium (137CS) source was used for gamma-irradiation. 
Whole-cell extracts were made using total extract (TOTEX) buffer (20 mM HEPES (pH 
7.9), 350 mM NaCl, 1 mM MgCl2, 0.5 mM EDTA, 0.1 mM EGTA, 0.5 mM DTT, 20% 
glycerol, and 1% NP-40). EMSAs and immunoblots were performed as described 
previously (Miyamoto et al., 1998; Jackson et al., 2015) and below. In Fig. 3A, the 
following antisera were used: anti-NEMO (FL-419; sc-8330 antibody; Santa Cruz); anti-
tubulin (CP06; EMD Millipore); anti-phospho-IκBα (5A5; #9246, Cell Signaling) 
 
NEMO reconstitution experiments. Exon 1B-edited cells (clone 1, 1.1 or 1.3) 
were seeded at ~60% density in a 60-mm tissue culture plates one day prior to transecting 
with the pcDNA-FLAG empty vector or pcDNA-FLAG-NEMO. Transfections were 
performed using Effectene Transfection Kit (QIAGEN) as follows: 0.2 µg plasmid, and 
1.6 µl Enhancer were diluted to a final volume of 32 µl with EC Buffer, and incubated 
for 5 min at room temperature for DNA condensation. Then, 2 µl Effectene was added, 
and samples were incubated for 7 min at room temperature to form Effectene-DNA 
complexes. The final transfection mixture was brought to 1.8 ml with DMEM/10% FBS, 
added to 60-mm plates containing 3.2 ml of fresh medium, and incubated overnight. 
Upon reaching confluence (2 days), transfected plates were subcultured into new plates at 
~60% density, and incubated again until cells reached confluence (2 days). Cells were 
then stimulated with 20 ng/ml recombinant TNFα (R&D Systems) diluted in PBS 
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containing 0.1% BSA for 10 min in a 37 °C, 5% CO2 in a humidified incubator. Cells 
were then lysed on ice and processed for Western blotting as described above. 
 
Nuclear extract preparation. To prepare nuclear fractions, cells were 
resuspended in 400 µl hypotonic buffer (10 mM HEPES pH 7.9, 1.5 mM MgCl2, 10 mM 
KCl), and were incubated on ice for 10 min. Samples were then supplemented with 55 µl 
NP-40, vortexed for 10 sec, and pelleted at 500 x g for 5 min at 4 °C. The nuclear pellet 
was washed with the hypotonic buffer, and re-pelleted as above. To lyse the nuclei, the 
pellet was resuspended in 60 µl high-salt buffer (20 mM HEPES pH 7.9, 1.5 mM MgCl2, 
0.2 mM EDTA, 420 mM NaCl, 25% v/v glycerol), vortexed for 30 sec, and samples were 
then rocked for 1 h at 4 °C. The nuclear extract was clarified by pelleting debris for 30 
min at 13,000 rpm at 4 °C. 
  
SUPPLEMENTAL MATERIAL 
Two Supplementary Tables and four Supplementary Figures. 
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FIG 1  General structure of the 5’ portion of the human NEMO gene. (A) Shown are the 
four 5’ alternative non-coding exons (1D, 1A, 1B, 1C) of the NEMO gene on 
chromosome X, as determined by Fusco et al. (2006). NEMO exon 1B has RNAPII, 
H3K4me3 and DNase hypersensitive site footprints in HEK 293 cells 
(https://www.encodeproject.org/experiments/ENCSR000DTU/; 
https://www.encodeproject.org/experiments/ENCSR000EJR/). (B) Downstream of  the 
NEMO exon 1B transcription start site (arrow) is a sequence (red) that aligns with a 
consensus motif (above the red box) that is found near transcription start site of many 
genes (Vo Ngoc et al. 2017a). 
 
 
 
 
 
 
29 
 
FIG 2  CRISPR/Cas9-based targeting of the exon 1b core promoter disrupts NEMO 
protein expression in 293T cells. (A) 293T cells that were infected with LentiCRISPR2.0 
construct containing no gRNA or the exon 1B gRNA (gRNA-Pool 1 and -2) were 
selected with puromycin, and puromycin-resistant pools of cells were then subjected to 
Western blotting for NEMO, β-tubulin (as a loading control), or FLAG-Cas9. (B) Shown 
is an anti-NEMO Western blot of control 293T cells, a 1:10 dilution of the control 
extract, and two clones (1 and 2) derived from 293T cells transduced with the 
LentiCRISPR-exon 1B virus. A Ponceau stain of the filter (as a loading control) is shown 
at the bottom. As a further control, a clone of puromycin-resistant cells targeted with a 
different gRNA were analyzed (C). (C) Sequencing of the targeted genomic locus in 
clone 1 cells was done by PCR amplification of the targeted site and Illumina-sequencing 
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of the PCR product. Shown are the wild-type reference sequence and the five most 
abundant genomic sequences. The complete array of deletions is shown in Fig. S1. (D) 
qPCR of NEMO transcripts (using exon 2 and 3 or exon 6 and 7 primers) was performed 
with RNA from control cells and clone 1 cells. The amount of NEMO mRNA is relative 
to the amount of RNA in control 293T cells (100). (E) RT-PCR using primers in exon 1B 
and the flanking intron 1 was performed with RNA from control and clone 1 cells. 
Products were then analyzed by gel electrophoresis and staining with ethidium bromide. 
As a control, shown also is an RT-PCR reaction for GAPDH mRNA. 
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FIG 3  Clone 1 cells are defective for canonical NF-κB activation in response to multiple 
activators. (A) Control 293T and clone 1 cells were treated with the indicated inducers of 
canonical NF-κB signaling, and extracts were then analyzed by EMSA for NF-κB and 
Oct1 DNA binding, or by Western blotting for NEMO, phospho-IκBα, and β-tubulin. 
Inducers are 10 ng/ml TNFɑ (T), 10 µM camptothecin (C), 10 µM VP16 (V), 25 µM 
doxorubicin (D) and 5 Gγ irradiation (I). (B) Clone 1 cells were transfected with pcDNA-
FLAG or pcDNA-FLAG-NEMO. Two days later, cells were treated with TNFα (+) or 
were left untreated (-). Western blotting of whole-cell extracts was done for phospho-
IκBα or for NEMO (top) or nuclear extracts (bottom) were probed for NF-κB p65. ns, 
non-specific band. Ponceau staining of the filters was performed to ensure approximately 
equal loading of protein extracts. 
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FIG 4  Isolation of cell subclones from clone 1 cells. (A) Five subclones of clone 1 cells 
were isolated and analyzed by Western blotting for NEMO. Shown also are control 293T 
and clone 1 cell extracts. (B) CRISPR sequencing of the PCR-amplified exon 1B core 
promoter in clones 1.1 and 1.3 was used to characterize the genomic disruptions (as done 
for Fig. 2C). (C) PCR-amplified exon 1B core promoter isolated from WT 293T and 
clone 1.1 cell genomic DNA was analyzed as Uncut or BsiE1-digested DNA. DNA was 
electrophoresed on a 1.5% agarose gel and was detected with ethidium bromide.  (D) 
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Clone 1.1 and 1.3 cells were transfected with pcDNA-FLAG or pcDNA-FLAG-NEMO. 
Two days later, cells were treated with TNFα (+) or were left untreated (-). Whole-cell 
extracts were analyzed for phospho-IκBα or NEMO expression. (E) Control 293T cells 
and clone 1.1 cells were transfected with pcDNA vector control or pcDNA-HA-NIK. 
Whole-cell extracts were subjected to Western blotting for HA-NIK, NEMO, and 
p100/p52. (F) Control 293T cells and clone 1.1 cell extracts were analyzed by Western 
blotting for FLAG-Cas9 (anti-FLAG). (G) Extracts from control 293T and clone 1.1 cells 
were analyzed by Western blotting for G6PD and NEMO. Where indicated, Ponceau 
staining of the filters was done to ensure approximately equal loading of total protein.  
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FIG 5  Targeting of the NEMO exon 1B core promoter with CRISPR/dCas9 reduced 
NEMO expression in 293T cells. (A) 293T cells were infected with a LentiCRISPR2.0-
dCas9 construct containing exon 1B gRNA, and transduced cells were selected with 
puromycin. Western blotting for NEMO was then performed on control cells (positive 
control 293T and 50% of the amount of 293T cell lysate, or negative control clone 1.1 
cells) or dCas9-infected pools (dP) or single cell clones (d1, d2, d3). (B) The indicated 
cell extracts were analyzed by Western blotting for G6PD and Cas9/dCas9. In both cases, 
Ponceau staining of the filters was done to ensure approximately equal loading of total 
protein. 
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FIG 6  Targeting of the NEMO exon 1B core promoter with CRISPR/Cas9 does not 
affect NEMO expression in liver cells. (A) SNU-423 cells were transduced with a 
LentiCRISPR2.0-Cas9 construct containing exon 1B gRNA, and transduced cells were 
selected with puromycin. A cell clone was picked and expanded. Western blotting for 
NEMO and Cas9 was then performed on wild-type (WT) control cell or the liver cell 
clone (L1) extracts, or the filter was stained with Ponceau for total protein. The numbers 
below the NEMO lanes indicate the relative amount of NEMO protein in the WT and LI 
lanes, as determined by scanning of the film with ImageJ. (B) PCR-amplified exon 1B 
core promoter from WT SNU-423 and clone L1 genomic DNA was analyzed as Uncut or 
BsiE1-digested DNA. DNA was electrophoresed on a 1.5% agarose gel and detected with 
ethidium bromide. (C) CRISPR sequencing of the PCR-amplified exon 1B core promoter 
in L1 genomic DNA was used to characterize the genomic disruptions (as done for Fig. 
2C.). (D) qPCR of NEMO transcripts was performed on cDNA isolated from WT and LI 
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clone SNU-423 cells, using primers for exons 2 and 3 or 6 and 7 (as described for Fig. 
2D). 
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TABLE S1. Plasmids used in this study. 
 
Plasmid Name Construction or Source 
LentiCRISPR v2.0 Sanjana et al. 2014 and Addgene 
Lenti-CRISPR-gRNA1 gRNA1 oligos were annealed and subcloned 
into the BsmBI site of Lenti-CRISPR v2.0 
Lenti-CRISPR-gRNA-C gRNA-C oligos were annealed and 
subcloned into the BsmBI site of Lenti-
CRISPR v2.0 
pCMV-dR8.91 Gag-pol helper virus plasmid (Zufferey et al., 
1997) 
pCMV-VSV-G Env helper virus plasmid (Addgene 8454) 
Lenti-CRISPR-dCas9 Mutations at codons 10 and 840 of Cas9 
were generated by three sequential rounds of 
overlap PCR using the 8 Cas9-codon primers 
listed in Table S2. An XbaI-BamHI fragment 
was then used to replace the analogous wild-
type Cas9 fragment in LentiCRISPRv2.0. 
Plasmid was deposited with Addgene, and 
verified by complete DNA sequencing. 
pSL1180 Intermediate vector (Amersham) used for 
subcloning of dCas9 mutant fragments, prior 
to subcloning back into LentiCRISPRv2.0 
pcDNA-FLAG Herscovitch et al., 2008 
pcDNA-FLAG-NEMO Herscovitch et al., 2008 
px330puro-HDR px330-puro was digested with BbsI and 
annealed oligos gRNA-Clone 1.1 (Table S1) 
were subcloned 
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TABLE S2. Oligonucleotides used in this study. 
 
Oligonucleotide 
Name 
Use DNA Sequence (5’-.3’) 
gRNA-1 (pair) CRISPR 
targeting of 
NEMO 
CACCGGGAAGGGCGACCGCGAAACT 
    CCCTTCCCGCTGGCGCTTTGACAAA    
gRNA-C (pair) CRISPR 
targeting control 
CACCGAGAGTCCGTCAGACGTGAGA 
    CTCTCAGGCAGTCTGCACTCTCAAA 
NEMO Exon 2 Fwd qPCR GCACCTGCCTTCAGAACAGG 
NEMO Exon 3 Rev qPCR ATCTGGTTGCTCTGCCGG 
NEMO Exon 6 Fwd qPCR GTGAGCGGAAGCGAGGAATG 
NEMO Exon 7 Rev qPCR AACGGTCTCCATCACAATCT 
NEMO Exon 1B 
Fwd 
RT-PCR CGGATCCCACAGCTATGACACCGGAAG 
NEMO Exon 2 Rev qPCR GAGGTGCCTATTCATCCAA 
GAPDH Fwd (exon 
7) 
RT-PCR, qPCR TGCACCACCAACTGCTTAGC 
GAPDH Rev  (exon 
8) 
RT-PCR, qPCR GGCATGGACTGTGGTCATGAG 
NEMO gExon 1B 
Fwd 
Genomic 
amplification for  
NGS 
GCCTCACACTTCTCGCCGGCTTCCC 
NEMO gIntron 1 
Rev 
Genomic 
amplification for 
NGS 
AGGACCACACCTGTCAGCAGAGTCCGTC 
gDNA Fwd Genomic 
amplification for 
BsiEI digestion 
CGGCGTGCTTATCATTACCGA 
gDNA Rev Genomic 
amplification for 
BsiEI digestion 
GTAGAAACAGTCCAGCTCGC 
Cas9-Codon 10-
Upstream 
Cloning of Cas9 
codon 10 
mutation 
GTTCCTGTTCCATTAACTGCG 
Cas9-Codon 10-Fwd Cas9 codon 10 
mutation 
TCGGCCTGGCCATCGGCACCAA 
Cas9-codon 10-Rev Cas9 codon 10 
mutation 
GTGCCGATGCCCAGGCCGAT 
Cas9-Codon 10-
Downstream 
Cloning of Cas9 
codon 10 
mutation 
GGGTCAGCACGATATCTTCCA 
Cas9-codon 840-
Upstream 
Cloning of Cas9 
codon 840 
mutation 
TGGAAGATATCGTGCTGACCC 
Cas9-codon 840-
Fwd 
Cas9 codon 840 
mutation 
ACGATGTGGACGCCATCGTGCCTCAGAGC 
Cas9-codon 840-Rev Cas9 codon 840 
mutation 
GCTCTGAGGCACGATGGCGTCCACATCGT   
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Cas9-codon 840-
Downstream 
Cloning of Cas9 
codon 840 
mutation 
AAGTTTGTTGCGCCGGAT 
gRNA-Clone 1.1 CRISPR 
targeting of 8-bp 
deletion in clone 
1.1 cells 
CACCGCGTGGTAGGGAAGGGCGACT 
    CGCACCATCCCTTCCCGCTGACAAA 
HDR-1.1 HDR in clone 
1.1 cells 
TGGGAGCGGCGGACTGTGAACGCTGGTA 
GGGCCCCGGCGCTCCGAGAAAGTCTCA 
GTTTCGCGGTCGCCCTTCCCTACCACGCT* 
 
*The 8-bp sequence for that will result in HDR-mediated restoration of the wild-type 
exon 1B promoter sequence is underlined, and the nearly PAM site mutation is indicated 
in red.  
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FIG S1 Full genomic profile of the targeted locus in clone 1 cells. Sequencing of the 
targeted genomic locus in clone 1 cells was done by PCR amplification of the targeted 
site and Next generation sequencing of the PCR product. Shown are the wild-type 
reference sequence and the 42 most abundant genomic sequences, based on 34,230 
sequence reads. The percentage of reads that correspond to each sequence is shown to the 
right. 
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FIG S2 BsiEI site (CGRYCG) in the targeted NEMO exon 1B core sequence (red), 
which was targeted by the gRNA (underlined).  
 
 
 
 
 
 
FIG S3 HDR-mediated repair of the 8-bp deletion in the NEMO promoter in clone 1.1 
cells. As in Fig. 2C, sequencing of the targeted genomic locus in a pool of transfected 
clone 1.1 cells was done by PCR amplification of the targeted site and next generation 
sequencing of the PCR product. Shown are the wild-type reference sequence (Ref.) and 
the five most abundant genomic sequences. The HDR-modified sequence (11.5% of 
reads) contains the PAM site mutation (designated by the red “a” and the arrow).  
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FIG S4 Targeting of the NEMO exon 1B promoter element does not affect NEMO 
expression in clones of SNU-423 human liver cells. As in Fig. 6, SNU-423 cells were 
transfected with a LentiCRISPR2.0-Cas9 construct containing no gRNA (Vector) or the 
exon 1B gRNA, and transfected cells were selected with puromycin. Individual cell 
clones were picked and expanded. Western blotting for NEMO, Cas9, and β-tubulin was 
then performed on extracts from the indicated SNU-423 cell clones.  
 
 
